Actively Recruiting
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Led by Sun Yat-sen University · Updated on 2024-08-13
60
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
Sponsors
S
Sun Yat-sen University
Lead Sponsor
C
Chinese PLA General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.
CONDITIONS
Official Title
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of primary hepatocellular carcinoma confirmed histologically or clinically
- Presence of oligometastasis diagnosed within three months of HCC diagnosis
- Metastases limited to five sites and no more than two organs involved, each with maximum diameter of 5 cm
- Received lenvatinib and PD-1 inhibitor as first-line systemic therapy for at least 3 months with controlled intrahepatic tumors and no progression of metastases
- Underwent locoregional treatments such as transarterial chemoembolization or hepatic arterial infusion chemotherapy
- Classified as Child-Pugh class A or B
- Eastern Cooperative Oncology Group performance status of 0 or 1
- No history of other malignancies
- Life expectancy of more than 3 months
- Hematologic and liver function parameters within specified limits
- Agreed to participate in this clinical trial
You will not qualify if you...
- Recurrent hepatocellular carcinoma
- Treated with lenvatinib and PD-1 inhibitor as second systemic therapy
- Age under 18 years or over 75 years
- More than five metastases
- No response to lenvatinib
- Metastases larger than 5 cm in size
- Life expectancy less than 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General hospital
Beijing, None Selected, China, 100853
Actively Recruiting
Research Team
Q
Qunfang Zhou, MD
CONTACT
F
Feng Duan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here